Intraclass differences among antihypertensive drugs

Annual Review of Pharmacology and Toxicology

Volumn 55, Issue , 2015, Pages 333-352

  Feldman, R D ^a   Hussain, Y ^a   Kuyper, L M ^b   McAlister, F A ^c   Padwal, R S ^c   Tobe, S W ^d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Calcium channel blockers; Diuretics; Hypertension; blockers

Indexed keywords

ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; THIAZIDE DIURETIC AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DRUG CLASSIFICATION; HUMAN; PRIORITY JOURNAL; REVIEW; STUDY DESIGN; ANIMAL; BLOOD PRESSURE; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; COMPLICATION; DRUG EFFECTS; HYPERTENSION; PATHOPHYSIOLOGY; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; HUMANS; HYPERTENSION; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 84920847070     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010814-124446     Document Type: Review

References (126)

1. Lawes CMM, VanderHoorn S, Rodgers A. 2008. Global burden of blood-pressure-related disease, 2001. Lancet 371:1513-18
2. Lawes CMM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. 2006. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J. Hypertens. 24:423-30
3. Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F. 2005. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 45:907-13
4. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, et al. 2008. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 336:1121
5. Law MR, Morris JK, Wald NJ. 2009. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338:b1665
6. Fretheim A, Odgaard-Jensen J, Brors O, Madsen S, Njolstad I, et al. 2012. Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis. BMC Med. 10:33
7. McAlister FA, Laupacis A, Wells GA, Sackett DL. 1999. Users guides to the medical literature: XIX. Applying clinical trial results: B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 282:1371-77
8. McAlister FA, Sackett DL. 2001. Active-control equivalence trials and antihypertensive agents. Am. J. Med. 111:553-58
9. Greene WL, Concato J, Feinstein AR. 2000. Claims of equivalence in medical research: Are they supported by the evidence? Ann. Intern. Med. 132:715-22
10. Bucher HC, Guyatt GH, Griffith LE, Walter SD. 1997. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J. Clin. Epidemiol. 50:683-91
11. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, et al. 2011. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 14:417-28
12. CollinsR, PetoR, MacMahon S, Hebert P, Fiebach NH, et al. 1990. Blood pressure, stroke, and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335:827-38
13. McAlister FA. 2002. Commentary: Relative treatment effects are consistent across the spectrum of underlying risks ⋯ usually. Int. J. Epidemiol. 31:76-77
14. Song F, Altman DG, Glenny AM, Deeks JJ. 2003. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326:472
15. Floyd JS, Psaty BM. 2012. Observational comparative effectiveness studies of drug therapies: high-quality answers or important clinical questions? Arch. Intern. Med. 172:1412-14
16. Shrank WH, Patrick AR, Brookhart MA. 2011. Healthy user and related biases in observational studies of preventive interventions: A primer for physicians. J. Gen. Intern. Med. 26:546-50
17. Beyer KH, Baer JE. 1961. Physiological basis for the action of newer diuretic agents. Pharmacol. Rev. 13:517-62
18. Tamargo J, Segura J, Ruilope LM. 2014. Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin. Pharmacother. 15:527-47
19. Mroczek WJ. 1983. Indapamide: clinical pharmacology, therapeutic efficacy in hypertension, and adverse effects. Pharmacotherapy 3:61-67
20. Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJG, Phillips BB, et al. 2006. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47:352-58
21. Ernst ME, Carter BL, Zheng S, Grimm RH Jr. 2010. Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am. J. Hypertens. 23:440-46
22. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. 2012. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 59:1104-9
23. Roush GC, Holford TR, Guddati AK. 2012. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 59:1110-17
24. Dhalla IA, GomesT, Yao Z, Nagge J, PersaudN, et al. 2013. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: A population-based cohort study. Ann. Intern. Med. 158:447-55
25. Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. 2011. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: A retrospective cohort analysis. Hypertension 57:689-94
26. Maione A, Navaneethan SD, Graziano G, Mitchell R, Johnson D, et al. 2011. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: A systematic review of randomized controlled trials. Nephrol. Dial. Transplant. 26:2827-47
27. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, Weaver WD. 2006. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: A systematic review and meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 47:1576-83
28. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, et al. 2000. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. Lancet 355:1575-81
29. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. 2000. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342:145-53
30. Verdecchia P, Angeli F, Cavallini C, Gattobigio R, Gentile G, et al. 2009. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: A meta-analysis. Eur. Heart J. 30:679-88
31. Unger T. 2002. The role of the renin-angiotensin system in the development of cardiovascular disease. Am. J. Cardiol. 89:3A-9A
32. Zaman MA, Oparil S, Calhoun DA. 2002. Drugs targeting the renin-angiotensin-aldosterone system. Nat. Rev. Drug Discov. 1:621-36
33. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlof B, et al. 2002. Pathophysiologic and therapeutic importance of tissue ACE: A consensus report. Cardiovasc. Drugs Ther. 16:149-60
34. Michel MC, Foster C, Brunner HR, Liu L. 2013. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol. Rev. 65:809-48
35. Fyhrquist F. 1986. Clinical pharmacology of the ACE inhibitors. Drugs 32(Suppl. 5):33-39
36. Brown NJ, Vaughan DE. 1998. Angiotensin-converting enzyme inhibitors. Circulation 97:1411-20
37. Heel RC, Brogden RN, Speight TM, Avery GS. 1980. Captopril: A preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 20:409-52
38. White CM. 1998. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 18:588-99
39. Ahuja K, Charap MH. 2010. Management of perioperative hypertensive urgencies with parenteral medications. J. Hosp. Med. 5:E11-16
40. Flack JM, Nasser SA. 2011. Benefits of once-daily therapies in the treatment of hypertension. Vasc. Health Risk Manag. 7:777-87
41. Furberg CD, Psaty BM. 2003. Should evidence-based proof of drug efficacy be extrapolated to a "class of agents"? Circulation 108:2608-10
42. Shah AD, Arora RR. 2005. Tissue angiotensin-converting enzyme inhibitors: Are they more effective than serum angiotensin-converting enzyme inhibitors? Clin. Cardiol. 28:551-55
43. Hilleman DE, Lucas BD Jr. 2004. Angiotensin-converting enzyme inhibitors and stroke risk: benefit beyond blood pressure reduction? Pharmacotherapy 24:1064-76
44. Sica DA. 2001. The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: Are their benefits a class effect or do individual agents differ? Curr. Opin. Nephrol. Hypertens. 10:597-601
45. Svensson P, de Faire U, Sleight P, Yusuf S, O'Stergren J. 2001. Comparative effects of ramipril on ambulatory and office blood pressures: A HOPE substudy. Hypertension 38:E28-32
46. Staessen JA, Wang JG, Thijs L. 2001. Cardiovascular protection and blood pressure reduction: A metaanalysis. Lancet 358:1305-15
47. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. 2008. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358:1547-59
48. McAlister FA. 2012. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: A collaborative meta-analysis of randomized trials. Eur. Heart J. 33:505-14
49. Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, et al. 2007. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J. Hypertens. 25:951-58
50. Siegl PK. 1993. Discovery of losartan, the first specific non-peptide angiotensin II receptor antagonist. J. Hypertens. Suppl. 11:S19-22
51. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. 1998. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am. J. Hypertens. 11:445-53
52. Takagi H, Niwa M, Mizuno Y, Goto SN, Umemoto T. 2013. A meta-analysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure. Hypertens. Res. 36:959-66
53. Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, et al. 2008. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am. J. Hypertens. 21:1157-62
54. Choi HK, Soriano LC, Zhang Y, Rodrguez LAG. 2012. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 344:d8190
55. Soltani Z, Rasheed K, Kapusta DR, Reisin E. 2013. Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: Is it time for reappraisal? Curr. Hypertens. Rep. 15:175-81
56. Derosa G, Cicero AFG, Dangelo A, Ragonesi PD, Ciccarelli L, et al. 2006. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-α. Hypertens. Res. 29:849-56
57. Murakami K, Wada J, Ogawa D, Horiguchi CS, Miyoshi T, et al. 2013. The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO). Diabetes Vasc. Dis. Res. 10:93-96
58. Suksomboon N, Poolsup N, Prasit T. 2012. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. J. Clin. Pharmacol. Ther. 37:319-27
59. Antoniou T, Camacho X, Yao Z, Gomes T, Juurlink DN, Mamdani MM. 2013. Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: A population-based cohort study. CMAJ 185:1035-41
60. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, et al. 2011. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N. Engl. J. Med. 364:907-17
61. Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, et al. 2011. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: A multicentre, randomised, placebocontrolled study. Diabetologia 54:2978-86
62. Padwal R, Lin M, Etminan M, Eurich DT. 2014. Comparative effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus: retrospective cohort study. Hypertension 63:977-83
63. US Food Drug Adm. 2013. Olmesartan Medoxomil: drug safety communication-label changes to include intestinal problems (sprue-like enteropathy). Silver Spring, MD: US Food Drug Adm. http://www. fda. gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm359528. htm
64. US Food Drug Adm. 2011. FDA drug safety communication: safety review update of Benicar (olmesartan) and cardiovascular events. Silver Spring, MD: US Food Drug Adm. http://www. fda. gov/Drugs/DrugSafety/ucm251268. htm
65. MERIT-HF Study Group. 1999. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-7
66. Freemantle N, Cleland J, Young P, Mason J, Harrison J. 1999. β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318:1730
67. Borer JS, Comerford MB, Sowton E. 1976. Assessment of metoprolol, a cardioselective beta-blocking agent, during chronic therapy in patients with angina pectoris. J. Int. Med. Res. 4:15-22
68. Khan N, McAlister FA. 2006. Re-examining the efficacy ofβ-blockers for the treatment of hypertension: A meta-analysis. CMAJ 174:1737-42
69. Messerli FH, Grossman E, Goldbourt U. 1998. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 279:1903-7
70. Kuyper LM, Khan NA. 2014. Atenolol vs nonatenolol β-blockers for the treatment of hypertension: A meta-analysis. Can. J. Cardiol. 30:S47-53
71. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, et al. 2006. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113:1213-25
72. Schiffrin EL, Deng LY, Larochelle P. 1994. Effects of a β-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 23:83-91
73. Kirstein SL, Insel PA. 2004. Autonomic nervous system pharmacogenomics: A progress report. Pharmacol. Rev. 56:31-52
74. Lund-Johansen P. 1979. Hemodynamic consequences of long-term beta-blocker therapy: A 5-year follow-up study of atenolol. J. Cardiovasc. Pharmacol. 1:487-95
75. Teisman ACH, van Veldhuisen DJ, Boomsma F, de Kam PJ, Tjeerdsma G, et al. 2000. Chronic betablocker treatment in patients with advanced heart failure: effects on neurohormones. Int. J. Cardiol. 73:7-12
76. Minneman KP, Pittman RN, Molinoff PB. 1981. β-adrenergic receptor subtypes: properties, distribution, and regulation. Annu. Rev. Neurosci. 4:419-61
77. Berglund G, Andersson O. 1981. Beta-blockers or diuretics in hypertension? A six year follow-up of blood pressure and metabolic side effects. Lancet 1:744-47
78. Bangalore S, Parkar S, Grossman E, Messerli FH. 2007. A meta-analysis of 94, 492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am. J. Cardiol. 100:1254-62
79. Poirier L, Lacourciere Y. 2012. The evolving role of β-adrenergic receptor blockers in managing hypertension. Can. J. Cardiol. 28:334-40
80. Ekbom T, Dahl of B, Hansson L, Lindholm LH, Schersten B, Wester PO. 1992. Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: A report from the STOP-Hypertension study. J. Hypertens. 10:1525-30
81. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, et al. 2004. Metabolic effects of carvedilol versus metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA 292:2227-36
82. Agabiti-Rosei E, Porteri E, Rizzoni D. 2009. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc. Health Risk Manag. 5:353-60
83. Mahmud A, Feely J. 2008. β-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am. J. Hypertens. 21:663-67
84. Jt. Natl. Comm. Detect. Eval. Treat. High Blood Press. 1993. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure ( JNC V). Arch. Intern. Med. 153:154-83
85. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, et al. 2007. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 28:1462-536
86. Hackam DG, Quinn RR, Ravani P, Rabi DM, Dasgupta K, et al. 2013. The 2013 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can. J. Cardiol. 29:528-42
87. Med. Res. Counc. Work. Party. 1985. MRC trial of treatment of mild hypertension: principal results. BMJ 291:97-104
88. Dahl of B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. 1991. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338:1281-85
89. Wikstrand J, Warnold I, Tuomilehto J, Olsson G, Barber HJ, et al. 1991. Metoprolol versus thiazide diuretics in hypertension: morbidity results from the MAPHY study. Hypertension 17:579-88
90. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, et al. 1987. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J. Hypertens. 5:561-72
91. Med. Res. Counc. Work. Party. 1992. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 304:405-12
92. Bangalore S, Sawhney S, Messerli FH. 2008. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J. Am. Coll. Cardiol. 52:1482-89
93. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, BeeversG, et al. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 359:995-1003
94. Dahlof B, Sever PS, Poulter NR, WedelH, Beevers DG, et al. 2005. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 366:895-906.
95. Lindholm LH, Carlberg B, Samuelsson O. 2005. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545-53
96. Natl. Clin. Guidel. Cent. 2011. Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. London: Natl. Clin. Guidel. Cent.
97. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, et al. 2014. 2014 evidencebased guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8). JAMA 311:507-20
98. UK Prospective Diabetes Study Group. 1998. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713
99. Ferrari R. 1997. Major differences among the three classes of calcium antagonists. Eur. Heart J. 18(Suppl. A):A56-70
100. Fleckenstein A. 1983. History of calcium antagonists. Circ. Res. 52:I3-16
101. Braunwald E. 1982. Mechanism of action of calcium-channel-blocking agents. N. Engl. J. Med. 307:1618-27
102. Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. 2005. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol. Rev. 57:411-25
103. Nelson CR, Knapp DA. 2000. Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension 36:600-3
104. Alderman MH, Cohen H, Roque R, Madhavan S. 1997. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 349:594-98
105. Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, et al. 1996. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 348:493-97
106. Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, et al. 1998. Calcium channel blockers and the risk of cancer. JAMA 279:1000-4
107. Bonny A, Lacombe F, Yitemben M, Discazeaux B, Donetti J, et al. 2008. The 2007 ESH/ESC guidelines for the management of arterial hypertension. J. Hypertens. 26:825-26
108. Campbell NR, Kaczorowski J, Lewanczuk RZ, Feldman R, Poirier L, et al. 2010. 2010 Canadian Hypertension Education Program (CHEP) recommendations: the scientific summary-an update of the 2010 theme and the science behind new CHEP recommendations. Can. J. Cardiol. 26:236-40
109. Wang JG, Kario K, Lau T, Wei YQ, Park CG, et al. 2011. Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian Pacific Heart Association. Hypertens. Res. 34:423-30
110. Bailey DG, Arnold JMO, Bend JR, Tran LT, Spence JD. 1995. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br. J. Clin. Pharmacol. 40:135-40
111. Sica DA. 2006. Interaction of grapefruit juice and calcium channel blockers. Am. J. Hypertens. 19:768-73
112. Williams DM, Cubeddu LX. 1988. Amlodipine pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. 28:990-94
113. Sica DA. 2001. Current concepts of pharmacotherapy in hypertension: combination calcium channel blocker therapy in the treatment of hypertension. J. Clin. Hypertens. 3:322-27
114. Weir MR. 2003. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J. Clin. Hypertens. 5:330-35
115. Sica DA. 2003. Calcium channel blocker-related periperal edema: Can it be resolved? J. Clin. Hypertens. 5:291-95
116. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, et al. 1997. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350:757-64
117. Wang JG, Staessen JA, Gong L, Liu L. 2000. Chinese trial on isolated systolic hypertension in the elderly. Arch. Intern. Med. 160:211-20
118. ALLHAT Off. Coord. ALLHAT Collab. Res. Group. 2002. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to PreventHeart Attack Trial (ALLHAT). JAMA 288:2981-97
119. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, et al. 2000. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 356:359-65
120. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, et al. 2003. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 290:2805-16
121. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, et al. 2003. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289:2073-82
122. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. 2009. Combination therapy versusmonotherapy in reducing blood pressure: meta-analysis on 11, 000 participants from 42 trials. Am. J. Med. 122:290-300
123. L opez-Send on J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, et al. 2004. Expert consensus document on β-adrenergic receptor blockers. Eur. Heart J. 25:1341-62
124. Dresser GK, Spence JD, Bailey DG. 2000. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38:41-57
125. Kelly JG, OMalley K. 1992. Clinical pharmacokinetics of calcium antagonists: an update. Clin. Pharmacokinet. 22:416-33
126. Bailey DG, Dresser GK. 2004. Interactions between grapefruit juice and cardiovascular drugs. Am. J. Cardiovasc. Drugs 4:281-97